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Abstract
Background: Adiponectin is a serum protein produced by  adipose tissue which exerts anti-inflamma-
tory, anti-diabetic and anti-atherosclerotic properties, hence is considered a cardio-protective marker. 
With the current uncertain role of adiponectin in dialysis patients to the aim of this study was to inves-
tigate its relationship with left ventricular (LV) structure and function in these patients.
Methods: This study included 89 (age 56 ± 13 years, 43% male) patients treated with regular dialy-
sis for > 6 months, and 55 control subjects with normal renal function. A complete two-dimensional, 
M-mode and tissue-Doppler echocardiographic study, and biochemical blood analyses, adiponectin and 
anthropometric parameters were obtainedon the same day.
Results: Dialysis patients had lower body mass index (BMI) and lower body surface area (BSA)  
(p < 0.001 for both), lower waist/hips ratio (p = 0.005), higher LV mass index (LVMI, p < 0.001), 
higher adiponectin level (p < 0.001) and LV end-systolic volume (p = 0.003), lower LV ejection fraction  
(p = 0.006), longer isovolumic relaxation time (p < 0.001), lower mean LV strain (p = 0.002), larger left 
atrium volume (p = 0.022) and lower left atrium emptying fraction (p = 0.026), compared to controls.  
In dialysis patients, adiponectin correlated with waist circumference (r = –0.427, p < 0.001), BMI  
(r = –0.403, p < 0.001) and BSA (r = –0.480, p < 0.001), and to a lesser extent with LVMI (r = 0.296, 
p = 0.005), waist/hips ratio (r = –0.222, p = 0.037) and total cholesterol (r = –0.292, p = 0.013). 
But in controls, it correlated only modestly with age (r = 0.304, p = 0.024), hemoglobin (r = 0.371,  
p = 0.005), high density lipoprotein cholesterol (r = 0.315, p = 0.019) and LVMI (r = 0.277, p = 0.043).
Conclusions: It seems that in dialysis patients, adiponectin modest correlation with anthropometric 
measurements suggests an ongoing catabolic process rather than a change in ventricular function. 
(Cardiol J 2018; 25, 4: 501–511)
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Introduction
Adiponectin, an adipocyte-derived hormone, 
is a serum protein produced by the adipose tissue 
[1, 2], and exerts anti-inflammatory, anti-diabetic and 
anti-atherosclerotic properties [3–6], and hence 
is considered a cardio-protective marker. Several 
previous studies suggested a possible influence 
of adiponectin in many clinical conditions, such 
as obesity, insulin resistance, hypertension, dys-
lipidemia and atherosclerotic heart disease [7–11]. 
Hypoadiponectinemia has been identified as inde-
pendent risk factor for cardiovascular (CV) disease 
[12, 13]. Adiponectin prevents progression of left 
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ventricular (LV) hypertrophy (LVH) [4, 14], which 
correlates with CV complications both in hyper-
tensive [15, 16] and chronic kidney disease (CKD) 
[17, 18]. While, it was found to normally correlate 
with blood pressure values, such a relationship in 
hypertensives remains controversial [11, 19–22]. 
On the other hand, adiponectin levels have been 
found to correlate with LV mass index (LVMI) 
[4, 23], and with impaired renal function [24–26], 
in patients with renal failure and those treated with 
dialysis, although modestly [24, 27]. The aim in this 
study therefore, was to investigate the relationship 
between adiponectin and LV structure and function 
measurements in dialysis patients, as an attempt 
to get more insight into its protective CV role in 
these patients.  
Methods
Patients
Eighty-nine consecutive patients treated with 
regular dialysis at the Dialysis Unit of the Univer-
sity Clinical Centre of Kosovo were included in this 
study (age 56 ± 13 [18–80] years, 43% male) and 
55 subjects, who had normal renal function,  and 
served as a control group which was recruited be-
tween May 2013 and April 2016. All subjects gave 
informed consent to participate in the study, which 
was approved by the Ethics Committee of Medical 
Faculty, University of Prishtina. All patients includ-
ed had been receiving chronic standardized dialysis 
500–750 mL/min dialysate flow, 250–300 mL/min 
blood flow, over 3–4 h session, 3 times per week, 
for at least 6 months prior to recruitment in the 
study. The dialysis potassium level was 2.0 mEq/L 
and calcium level was 1.75 mEq/L. Patients with 
active malignancy, decompensated heart failure, 
hepatic or pulmonary disease, pregnant women 
and those with failed transplant were excluded 
from the study. Blood pressure was recorded with 
a brachial sphygmomanometer after subjects had 
rested in the supine position for at least 10 min. 
Clinical data
For all participants, demographic details, 
physical examination and anthropometric measure-
ments were taken. Hypertension was defined as 
systolic blood pressure ≥ 140 mmHg, and/or dias-
tolic blood pressure ≥ 90 mm Hg, or when patients 
were using antihypertensive therapy. Diabetes was 
defined as fasting plasma glucose ≥ 126 mg/dL 
(> 7 mmol/L) or the use of hypoglycemic medications. 
Body mass index (BMI) was measured after the 
dialysis session and was calculated by dividing 
dry weight by body height (kg/m2). Twelve lead 
electrocardiogram was also recorded in all patients 
and QRS duration was measured. 
Blood analysis
Blood urea nitrogen, creatinine, albumin, total 
protein, total cholesterol, triglyceride, calcium, 
phosphate, iron, hematocrit and hemoglobin were 
measured using standard methods. High density 
lipoprotein cholesterol (HDL-L) was measured 
by homogeneous enzymatic colorimetric assay 
(COBAS INTEGRA® 400 plus, Roche), parathyroid 
hormone by immunoassay (COBAS e 411 analyzer-
Roche) and C-reactive protein (CRP) by particle 
enhanced turbidimetric assay (COBAS INTEGRA® 
400 plus, Roche). All samples for a given assay 
were tested simultaneously, in duplicate and in 
appropriate dilutions, according to conventional 
protocols. 
Adiponectin measurement 
Venous blood samples were withdrawn from 
each subject after ≥ 8 h of fasting. The samples 
were stored at –80°C until analyzed. Serum adi-
ponectin concentration was measured by ELISA 
Microplate Reader Gea Linear. Intra- and inter-
assay coefficient of variation was below 3.0% and 
5.1%, respectively [28].
Cardiac structure and function:
Left ventricular structure measurements. 
Echocardiographic examination in all patients and 
in controls was performed on the same day of 
dialysis using a Philips iE33 system with a multi-
frequency transducer and harmonic imaging as ap-
propriate. Images were obtained with the patient in 
the left lateral decubitus position and during quiet 
expiration. LV volumes and ejection fraction (EF) 
were calculated from the apical 2- and 4-chamber 
views using the modified Simpson method. Left 
ventricular mass (LVM) was estimated using the 
anatomically validated formula of Devereux et al. 
[29, 30] and was indexed to height 2.7 (LVMI) [31]: 
LVM [g] = 0.8 × (1.04 × (LVEDD + PWTD + 
+ IVSTD)3 – (LVEDD)3) + 0.6 [30]. LVH was defined 
as a LVMI of 47 g/m2.7 for women and 53 g/m2.7 for 
men [32]. LVM normalized for body surface area 
(LVM/BSA) was also calculated as g/m2. 
Left ventricular function measurements. 
From the spectral wave Doppler LV filling, peak 
E wave velocity, peak A wave velocity, the ratio 
between peak E and A velocities (E/A ratio), and E 
wave deceleration time were measured. From tis-
sue-Doppler imaging recordings, peak systolic (s’), 
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and early diastolic (e’) and late diastolic (a’) 
mitral annular velocities were also measured. 
The ratio of trans-mitral to myocardial early di-
astolic peak velocity (E/e’) was calculated, after 
averaging septal and lateral e’velocities [33, 34], 
to reflect filling pressures. Mitral annular plane 
systolic excursion (MAPSE) was measured by 
placing the M-mode cursor at the lateral and 
septal angles.
Total LV filling time (FT) was measured from 
the onset of the E wave to the end of the A wave 
and ejection time (ET) from the onset to the end of 
the aortic Doppler flow velocity. Total isovolumic 
time (t-IVT) was calculated as 60 – (total ET + total 
FT) and was expressed in s/min [35]. Tei index was 
calculated as the ratio between t-IVT and ET [36]. 
LV isovolumic relaxation time (IVRT) was meas-
ured as the time interval between LV end-ejection 
(from the pulsed-wave Doppler recording of the 
outflow tract velocity) and the onset of transmitral 
E-wave velocity. 
The diameter of the LV outflow tract (LVOT) 
was measured from the parasternal long axis view 
as the distance between the bases of the aortic 
valve cusp during systole. The LVOT area was 
then calculated using the formula: LVOT area = 
= [(LVOT diameter average/2)2] × 3.14.
The average velocity time integral (VTI) was 
measured using the pulsed wave Doppler samples 
obtained at the center of the LVOT from the api-
cal view. The stroke volume was calculated as the 
product of the LVOT area and the VTI of the LVOT 
blood flow. 
Left atrial (LA) measurements. LA diameter 
was measured from aortic root recordings with the 
M-mode cursor positioned at the level of the aortic 
valve leaflets. LA volumes were measured using 
area-length method from the apical four chamber 
views, according to the guidelines of the American 
Society of Echocardiography and European As-
sociation of Echocardiography [22, 37]. Left atrial 
maximal volume (LAV max) was measured at the 
end of LV systole, just before the opening of the 
mitral valve, LA minimal volume (LAV min) was 
measured at end diastole, immediately after mitral 
valve closure. LA total emptying fraction was cal-
culated using the formula [38]: LA total emptying 
fraction = LAV max – LAV min/LAV max × 100.
Statistical analysis 
Values are expressed as means ± standard 
deviation. Differences between the two groups 
were analyzed using the unpaired Student t test 
following the analysis of variance. P values < 0.05 
were considered statistically significant. The c2 
test was used to compare the categorical variables. 
Pearson correlations were performed to identify 
the simple correlations between adiponectin and 
the other variables. Subjects were stratified into 
four groups based on the dialysis treatment and 
on the presence of LVH on the echocardiographic 
examination: Group 1 (dialysis patients with LVH), 
Group 2 (dialysis patients without LVH), Group 3 
(non-dialysis patients with LVH) and Group 4 
(non-dialysis patients without LVH). A one-way 
ANOVA with Bonferroni correction was performed 
to compare continuous variables. All analyses were 
performed using SPSS 22 for windows. 
Results
Clinical data of dialysis patients versus  
controls (Table 1)
The baseline demographic, anthropometric 
and clinical data of dialysis patients and controls 
are shown in Table 1. The age, gender and CV 
risk factors (smoking, diabetes, arterial hyper-
tension and cholesterol level) were not different 
between groups. The dialysis patients had lower 
BMI and lower BSA (p < 0.001 for both), smaller 
waist measurements (p < 0.001), smaller inter-
hip distance (p = 0.002), lower waist/hip ratio (p 
= 0.005), higher SBP and DBP (p = 0.002 and 
p = 0.018, respectively), higher baseline heart 
rate, higher CRP level, lower red blood cell 
(RBC), lower hemoglobin, lower albumin level, 
lower hematocrit and higher adiponectin level 
(p < 0.001, for all), lower blood iron level (p = 
= 0.028), and higher fasting glucose (p = 0.005) 
compared to controls. Less dialysis patients were 
treated with beta-blockers (p < 0.001), and more 
treated with angiotensin converting enzyme 
inhibitors (p = 0.003) and calcium antagonists 
(p < 0.001), compared to controls. 
Cardiac function of dialysis patients versus 
controls (Table 2)
Dialysis patients had higher LVMI (p < 0.001), 
thicker interventricular septum (p = 0.006), larger 
LV end-systolic volume (p = 0.003), lower LVEF 
(p = 0.006), shorter LVET (p < 0.001), longer 
IVRT (p < 0.001), lower Tei index (p = 0.003), 
lower septal MAPSE (p = 0.036), higher A wave 
(p = 0.009), lower septal e’ (p = 0.017), larger LA 
volume (p = 0.022) and lower LA emptying fraction 
(p = 0.026), compared to controls.
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Table 1. Clinical and biochemical data in dialysis patients versus controls.
Variable Controls (n = 55) Dialysis patients (n = 89) P 
Age [years] 55 ± 13 56 ± 13 0.839
Gender [male, %] 56 43 0.111
Smoking [%] 31 20 0.146
Diabetes [%] 11 18 0.252
Hypertension [%] 40 56 0.059
SBP [mm Hg] 141 ± 20 153 ± 24 0.002
DBP [mm Hg] 87 ± 10 82 ± 13 0.018
Beta-blockers [%] 29 5.6 < 0.001
ACE-inhibitor [%] 24 47 0.003
Rocaltrol [%] 0 95 < 0.001
Calcium carbonate [%] 4 98 < 0.001
Aspirin [%] 42 9 < 0.001
Ca-channel blockers [%] 2 29 < 0.001
Diuretic [%] 20 10 0.096
Heart rate [bpm] 73 ± 10 80 ± 13 < 0.001
Waist [cm] 96 ± 11 88 ± 12 < 0.001
Hips [cm] 105 ± 11 99 ± 12 0.002
Waist/hip ratio 0.92 ± 0.06 0.89 ± 0.05 0.005
Weight [kg] 80 ± 13 67 ± 14 < 0.001
Body mass index [kg/m2] 27 ± 3.4 24 ± 4.4 < 0.001
Body surface area [m2] 1.1 ± 0.2 0.9 ± 0.2 < 0.001
Adiponectin [µg/mL] 5.9 ± 3 15 ± 9 < 0.001
C-reactive protein [mg/L] 3.4 ± 3 11 ± 20 < 0.001
HDL-cholesterol [mmol/L] 1.0 ± 0.5 0.9 ± 0.3 0.097
Total cholesterol [mmol/L] 4.8 ± 0.8 4.5 ± 0.9 0.108
Triglyceride [mmol/L] 1.6 ± 0.5 1.8 ± 0.8 0.030
Creatinine [umol/L] 80 ± 16 711 ± 160 < 0.001
Blood urea nitrogen [mmol/L] 5.4 ± 1.4 27 ± 5.3 < 0.001
Parathormone [pg/mL] 39 ± 26 126 ± 114 0.012
Phosphorus [mg/dL] 1.0 ± 0.07 1.6 ± 0.5 < 0.001
Total calcium [mmol/L] 2.2 ± 0.15 2.1 ± 0.3 0.428
Iron [µmol/L] 19 ± 4.9 16 ± 8.3 0.028
Fasting glucose [mmol/L] 5.6 ± 1.5 6.9 ± 3.9 0.005
Total protein [g/L] 66 ± 2.6 65 ± 5.4 0.438
Albumin [g/L] 40 ± 4 37 ± 4 < 0.001
Aspartate aminotransferase [U/L] 18 ± 6 20 ± 16 0.291
Alanine aminotransferase [U/L] 20 ± 8 23 ± 21 0.148
Red blood cells ×106/L 4.5 ± 0.6 3.5 ± 0.9 < 0.001
White blood cells ×103/L 7.7 ± 1.3 7.5 ± 3.2 0.594
Hemoglobin [g/dL] 14 ± 1.3 10 ± 1.6 < 0.001
Hematocrit [%] 39 ± 6.1 33 ± 5.5 < 0.001
SBP — systolic blood pressure; DBP — diastolic blood pressure; ACE — angiotensin converting enzyme; HDL — high-density lipoprotein
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Dialysis patients with LVH versus  
without LVH (Tables 3, 4)
In addition to the increased LVM and LVMI, 
the dialysis patients with LVH had lower weight, 
lower BSA, higher blood iron level, larger LV end 
diastolic volume, higher LVEF and LV stroke vol-
ume (p < 0.05, for all) compared to dialysis patients 
without LVH. All the other clinical, biochemical 
and echocardiographic indices were not different 
between the two groups.
Table 2. Echocardiographic data in controls group vs. dialysis patients.
Variable Controls (n = 55) Dialysis patients (n = 89) P 
LV dimension and mass
LV mass [g] 214 ± 75 230 ± 66 0.201
LV mass index [g/m2.7] 47 ± 13 68± 29 < 0.001
Inter ventricular septum [cm] 1.2 ± 0.16 1.25 ± 0.2 0.006
LV posterior wall [cm] 1.0 ± 0.1 1.1 ± 0.2 0.095
End diastolic volume [mL] 113 ± 22 119 ± 35 0.212
End systolic volume [mL] 39 ± 14 48 ± 23 0.003
LV systolic function
LV ejection fraction [%] 64 ± 7.7 60 ± 10 0.006
LV shortening fraction [%] 34 ± 5.1 32 ± 6.5 0.071
Stroke volume [mL] 72 ± 19 71 ± 19 0.809
Ejection time [ms] 315 ± 42 279 ± 42 < 0.001
Tei index 0.37±0.2 0.36 ± 0.3 0.003
Lateral s’ [cm/s] 7.1 ± 1.9 6.8 ± 1.8 0.468
Septal s’ [cm/s] 6.1 ± 1.5 5.7 ± 1.5 0.142
Septal MAPSE [cm] 1.4 ± 0.3 1.3 ± 0.3 0.036
Lateral MAPSE [cm] 1.6 ± 0.3 1.5 ± 0.3 0.077
LV diastolic function
IVRT [ms] 101 ± 28 127 ± 30 < 0.001
E wave [cm/s] 57 ± 14 56 ± 18 0.692
A wave [cm/s] 64 ± 16 72 ± 18 0.009
E/A ratio 0.9 ± 0.6 0.9 ± 0.7 0.783
EDT [ms] 174 ± 40 178 ± 50 0.545
Lateral e’ [cm/s] 8.1 ± 2.9 7.8 ± 3.3 0.627
Lateral a’ [cm/s] 9.2 ± 2.4 9.3 ± 2.9 0.730
E/e’ ratio 8.3 ± 2.3 9.2 ± 3.9 0.092
Septal e’ [cm/s] 6.5± 2.0 5.7± 2.0 0.017
Septal a’ [cm/s] 7.9 ± 1.5 7.9 ± 2.5 0.921
LA dimension and function
LA diameter [cm] 3.7 ± 0.3 3.9 ± 0.5 0.090
Maximal LA volume [mL] 52 ± 16 56 ± 22 0.213
Minimal LA volume [mL] 19 ± 8 23 ± 14 0.022
LA emptying fraction [%] 65 ± 8 60 ± 11 0.026
Aortic measurements
Aorta [cm] 3.4 ± 0.3 3.4 ± 0.4 0.543
Ascending aorta [cm] 3.5 ± 0.3 3.6 ± 0.4 0.125
LV — left ventricular; LA — left atrium; MAPSE — mitral annular plane systolic excursion; IVRT — isovolumic relaxation time; RV — right  
ventricular; EDT — E wave deceleration time; A — atrial velocity; a’ — late diastolic myocardial velocity; E — early mitral inflow velocity;  
e’ — early diastolic myocardial velocity; s’ — systolic myocardial velocity
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Dialysis patients with LVH versus non-dialysis 
patients with LVH (Tables 3. 4)
Dialysis patients with LVH, had higher adi-
ponectin (Fig. 1), lower HDL-C, lower hemoglobin 
and RBC, shorter LVET (p < 0.001, for all), lower 
weight/hip ratio, lower BMI and BSA, lower hema-
tocrit, lower baseline heart rate and broader QRS 
complex (p < 0.05 for all), compared to non-dialysis 
LVH patients. All other clinical, biochemical and 
echocardiographic indices did not differ between 
the two groups. 
Table 3. Clinical, anthropometrical and biochemical data in study subjects.
Variable Group 1  
(n = 65)
Group 2  
(n = 24)
Group 3  
(n = 25)
Group 4  
(n = 30)
P 
Age [years] 56 ± 13 54 ± 13 59 ± 13 52 ± 13 0.186
SBP [mmHg] 155 ± 25 148 ± 21 146 ± 21 136 ± 183 0.004
DBP [mmHg] 83 ± 14 81 ± 11 88 ± 10 86 ± 9 0.098
Heart rate [bpm] 80 ± 13 83 ± 12 78 ± 11 76 ± 9 < 0.001
Waist [cm] 87 ± 13 92 ± 10 95 ± 122 97 ± 11c < 0.001
Hips [cm] 97 ± 12 103 ± 11 102 ± 12 107 ± 9c < 0.001
Waist/hips ratio 0.89 ± 0.06 0.89 ± 0.06 0.93 ± 0.062 0.91 ± 0.07 0.030
Weight [kg] 64 ± 13 74 ± 131 73 ± 112 85 ± 12c,5,6 < 0.001
Body mass index [kg/m2] 24 ± 5 25 ± 4 27 ± 32 28 ± 3c < 0.001
Body surface area [m2] 0.9 ± 0.2 1.0 ± 0.21 1.0 ± 0.182 1.1 ± 0.18c,5,6 < 0.001
Adiponectin [µg/mL] 16 ± 8.6 13 ± 8.9 6.8 ± 2.5b,4 5.1 ± 2.8c,e < 0.001
C-reactive protein [mg/L] 12 ± 9 9 ± 4 4 ± 3 3 ± 2 0.037
HDL-cholesterol [mmol/L] 0.9 ± 0.2 1.0 ± 0.4 1.2 ± 0.6b 0.8 ± 0.3f < 0.001
Total cholesterol [mmol/L] 4.5 ± 0.95 4.7 ± 0.97 4.7 ± 1.0 4.8 ± 0.65 0.294
Triglyceride [mmol/L] 1.8 ± 0.8 2.0 ± 0.8 1.5 ± 0.6 1.7 ± 0.4 0.108
Creatinine [µmol/L] 703 ± 170 733 ± 125 80 ± 18b, d 79 ± 15c,e < 0.001
Blood urea nitrogen [mmol/L] 27 ± 6 27 ± 5 5.5 ± 1.7b,d 5.3 ± 1.1c,e < 0.001
Total calcium [mmol/L] 2.1 ± 0.4 2.2 ± 0.2 2.2 ± 0.1 2.2 ± 0.2 0.698
Iron [µmol/L] 18 ± 9 13 ± 61 18 ± 3 20 ± 65 0.005
Fasting glucose [mmol/L] 7.2 ± 4.0 6.2 ± 3.2 5.5 ± 0.6 5.7 ± 1.9 0.062
Albumin [g/L] 40 ± 4 40 ± 3 38 ± 2 37 ± 43 0.003
Total proteins [g/L] 65 ± 5 64 ± 6 66 ± 2 66 ± 3 0.213
Aspartate aminotransferase [U/L] 22 ± 18 15 ± 5 18 ± 6 18 ± 5 0.169
Alanine aminotransferase [U/L] 26 ± 23 16 ± 9 19 ± 8 20 ± 8 0.078
Red blood cells [×106/uL] 3.4 ± 0.7 3.6 ± 1.2 4.3 ± 0.6b,4 4.7 ± 0.5c,e < 0.001
White blood cells [×103/uL] 7.6 ± 3.7 7.0 ± 1.3 7.5 ± 1.3 7.8 ± 1.2 0.755
Hematocrit [%] 33 ± 5.5 32 ± 5.4 38 ± 4.22,4 40 ± 7.3c,e < 0.001
Hemoglobin [g/dL] 10 ± 1.7 10 ± 1.5 13 ± 1.6b,d 14 ± 0.8c,e < 0.001
(1): p < 0.05 gr. 1 vs. gr. 2; (2): p < 0.05 gr. 1 vs. gr. 3; (3): p < 0.05 gr. 1 vs. gr. 4; (4): p < 0.05 gr. 2 vs. gr. 3; (5): p< 0.05 gr. 2 vs. gr. 4;  
(6): p < 0.05 gr. 3 vs. gr. 4
(a): p < 0.001 gr. 1 vs. gr. 2; (b): p < 0.001 gr. 1 vs. gr. 3; (c): p < 0.001 gr. 1 vs. gr. 4; (d) p < 0.001 gr. 2 vs. gr. 3; (e): p < 0.001 gr. 2 vs. gr. 4;  
(f): p < 0.001 gr. 3 vs. gr. 4
Gr. 1 — dialysis patients with LV hypertrophy; Gr. 2 — dialysis patients without LV hypertrophy; Gr. 3 — non-dialysis with LV hypertrophy;  
Gr. 4 — non-dialysis without LV hypertrophy 
LV — left ventricular; SBP — systolic blood pressure; DBP — diastolic blood pressure; ACE — angiotensin converting enzyme; HDL — high-
-density lipoprotein
Relationship of adiponectin with clinical, 
biochemical and cardiac function indices  
In dialysis patients versus controls (Table 5)
In all study patients, adiponectin had strong 
correlation with LVMI (p < 0.001) (Fig. 2). In di-
alysis patients, adiponectin had a strong correlation 
with anthropometric parameters (waist measures, 
BMI and BSA, p < 0.001, for all) (Figs. 3, 4), good 
correlation with LVMI (p = 0.005) (Fig. 5), but 
weak  correlation with waist/hips ratio (p = 0.037) 
and with total cholesterol level (p = 0.013). On the 
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Table 4. Echocardiographic data of study subjects.
Variable Group 1  
(n = 65)
Group 2  
(n = 24)
Group 3  
(n = 25)
Group 4  
(n = 30)
P 
LV dimension and mass
LVM [g] 245 ± 66 190 ± 451 237 ± 100 196 ± 393 < 0.001
LVMI [g/m2.7] 78 ± 27 41 ± 5a 59 ± 10b,4 38 ± 7c,f < 0.001
Interventricular septum [cm] 1.3 ± 0.25 1.1 ± 0.14 1.2 ± 0.17 1.1 ± 0.143 < 0.001
LV posterior wall [cm] 1.1 ± 0.17 1.0 ± 0.13 1.0 ± 0.13 1.0 ± 0.14 0.039
End diastolic volume [mL] 125 ± 37 105 ± 261 115 ± 21 112 ± 23 0.032
End systolic volume [mL] 50 ± 24 44 ± 21 43 ± 144 35 ± 133 0.016
LV systolic function
LV ejection fraction [%] 61 ± 8 59 ± 121 62 ± 7 66 ± 83,5 0.012
LV shortening fraction [%] 33 ± 6 31 ± 8 33 ± 5 35 ± 5 0.099
Stroke volume [mL] 75 ± 19 61 ± 181 68 ± 22 74 ± 17 0.010
Filling time [ms] 391 ± 95 375 ± 74 434 ± 117 397 ± 80 0.144
Ejection time [ms] 278 ± 43 282 ± 40 324 ± 50b,4 308 ± 333 < 0.001
Tei index 0.39 ± 0.3 0.30 ± 0.2 0.34 ± 0.2 0.40 ± 0.2 0.396
t-IVT [ms] 7.8 ± 3.8 6.8 ± 3.3 6.6 ± 4 8.7 ± 4.5 0.162
Lateral s’ [cm] 6.9 ± 1.9 6.7 ± 1.6 6.5 ± 1.7 7.5 ± 1.9 0.189
Septal s’ [cm/s] 5.5 ± 1.4 6.5 ± 1.5 5.3 ± 1.0 6.8 ± 1.5 < 0.001
Septal MAPSE [cm] 1.3 ± 0.3 1.4 ± 0.3 1.4 ± 0.3 1.5 ± 0.33 0.014
Lateral MAPSE [cm] 1.5 ± 0.3 1.6 ± 0.3 1.6 ± 0.3 1.6 ± 0.2 0.199
LV diastolic function
IVRT [ms] 128 ± 32 127 ± 28 100 ± 292,4 102 ± 27c,5 < 0.001
E wave [cm/s] 57 ± 20 53 ± 12 56 ± 13 58 ± 153 0.734
A wave [cm/s] 73 ± 19 70 ± 14 68 ± 17 61 ± 15 0.021
E/A 0.9 ± 0.7 0.8 ± 0.3 0.8 ± 0.3 1.0 ± 0.7 0.729
EDT [ms] 185 ± 53 163 ± 38 176 ± 46 171 ± 34 0.241
Lateral e’ [cm/s] 7.7 ± 3.2 8.2 ± 3.7 7.3 ± 2.2 8.7 ± 3.3 0.323
Lateral a’ [cm/s] 9.1 ± 2.7 10 ± 3.2 9.1 ± 2.4 9.2 ± 2.4 0.458
Lateral s’ [cm/s] 6.9 ± 1.9 6.7 ± 1.6 6.5 ± 1.7 7.5 ± 1.9 0.189
Septal e’ [cm/s]
Septal a’ [cm/s] 8 ± 2.4 9 ± 2.6 8 ± 1.6 8 ± 1.3 0.182
Septal s’ [cm/s] 6 ± 1.4 6 ± 1.5 5 ± 1.04 7 ± 1.5c,f < 0.001
LA dimension and function
LA diameter [cm] 3.9 ± 0.5 3.8 ± 0.5 3.7 ± 0.3 3.7 ± 0.3   0.383
LA maximal volume [mL] 52.5 ± 16 61 ± 28 56 ± 23 53 ± 20 0.558
LA minimal volume [mL] 19 ± 9 26 ± 17 23 ± 13 24 ± 15 0.353
LA emptying fraction [%] 65 ± 10 62 ± 11 61 ± 9 56 ± 13 0.080
Aortic measurement
Aorta [cm] 3.6 ± 0.4 3.5 ± 0.4 3.4 ± 0.3 3.4 ± 0.3 0.704
(1): p < 0.05 gr. 1 vs. gr. 2; (2): p < 0.05 gr. 1 vs. gr. 3; (3): p < 0.05 gr. 1 vs. gr. 4; (4): p < 0.05 gr. 2 vs. gr. 3; (5): p < 0.05 gr. 2 vs. gr. 4;  
(6): p < 0.05 gr. 3 vs. gr. 4
(a): p < 0.001 gr. 1 vs. gr. 2; (b): p < 0.001 gr. 1 vs. gr. 3; (c): p < 0.001 gr. 1 vs. gr. 4; (d): p < 0.001 gr. 2 vs. gr. 3; (e): p < 0.001 gr. 2 vs. gr. 4; 
(f): p < 0.001 gr. 3 vs. gr. 4
Gr. 1 — hemodialysis with LV hypertrophy; Gr. 2 — emodialysis without LV hypertrophy; Gr. 3 — non hemodialysis with LV hypertrophy; 
Group 4 — non hemodialysis without LV hypertrophy
LV — left ventricular; LVM — left ventricular mass; LVMI — left ventricular mass index; LA — left atrium; RV — right ventricle; MAPSE — 
mitral annular plane systolic excursion; IVRT — isovolumic relaxation time; t-IVT — total isovolumic time; EDT — E wave deceleration time; 
A — atrial diastolic velocity; a’ — late diastolic myocardial velocity; E — early mitral inflow velocity; e’ — early diastolic myocardial velocity; 
s’ — systolic myocardial velocity
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Table 5. Correlation of adiponectin with clinical, biochemical and echocardiographic variables in study 
patients.
Variable All study patients  
(n = 145)
Controls 
 (n = 55)
Dialysis patients  
(n = 89)
r p r p r p
Age 0.008 0.922 0.304 0.024 0.056 0.599
SBP 0.184 0.027 0.122 0.373 0.042 0.697
DBP –0.099 0.238 0.075 0.586 –0.001 0.993
C-reactive protein 0.068 0.420 0.211 0.121 0.112 0.298
Cholesterol –0.252 0.002 0.052 0.707 –0.292 0.013
HDL cholesterol 0.051 0.545 0.315 0.019 0.195 0.067
Hemoglobin –0.427 < 0.001 0.371 0.005 –0.020 0.853
Urea 0.499 < 0.001 –0.153 0.266 –0.037 0.730
Creatinine 0.494 < 0.001 –0.084 0.544 –0.066 0.541
Waist –0.461 < 0.001 –0.141 0.304 –0.427 < 0.001
Waist/hips ratio –0.283 0.001 –0.184 0.178 –0.222 0.037
Body mass index –0.468 < 0.001 –0.093 0.498 –0.403 < 0.001
Body surface area –0.522 < 0.001 –0.096 0.487 –0.480 < 0.001
Left atrium 0.065 0.437 –0.075 0.585 0.001 0.996
Ejection fraction –0.107 0.201 –0.162 0.237 0.044 0.684
Left ventricular mass 0.076 0.369 0.178 0.197 –0.013 0.904
LVMI 0.440 < 0.001 0.277 0.043 0.296 0.005
SBP — systolic blood pressure; DBP — diastolic blood pressure; HDL — high-density lipoprotein; LVMI — left ventricular mass index
Figure 1. Adiponectin level in study groups of patients; 
1 — Group 1 (dialysis patients with LVH; 2 — Group 2 
(dialysis patients without LVH); 3 — Group 3 (non-dialy-
sis patients with LVH); 4 — Group 4 (non-dialysis patients 
without LVH); LVH — left ventricular hypertherapy.
other hand, in controls, adiponectin only modestly 
correlated with age (p = 0.024), hemoglobin (p = 
0.005), HDL-C (p = 0.019), and LVMI (p = 0.043) 
(Fig. 5), but no relationship was noted with the 
other clinical, biochemical and echocardiographic 
parameters.
Discussion 
The findings of this study can be summarized 
as follows: dialysis patients had lower BSA and 
BMI compared to age and gender matched controls 
but did have a larger LV cavity with thicker walls, 
higher LVMI and broader QRS duration. In addition, 
they were more anemic and had higher adiponectin 
levels compared to controls. Finally, while in dialy-
sis patients adiponectin strongly correlated with 
BMI, it only modestly correlated with LVMI and 
volumes. The only relevant relationship in controls 
was with LVMI, although to a lesser strength than 
with dialysis patients.
Data interpretation. As expected, dialysis 
patients had lower body weight and BMI consistent 
with an element of cachexia, which is well known 
in patients with chronic kidney disease [39]. The 
profound degree of LVH resulting in higher mass 
index, again is consistent with the commonly found 
hypertension in this condition [40]. Such changes 
in LV structure resulted in significant functional 
disturbances in the form of reduced subendo-
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Figure 3. Correlation of adiponectin with body mass 
index (BMI) in dialysis patients and controls.
cardial function reflected on the MAPSE and its 
myocardial velocities, enlargement of LV volume, 
lower ejection fraction and left atrial enlargement, 
typical to what is commonly seen in hypertensive 
LV disease without kidney failure [41]. Further-
more, the dialysis patients had some degree of 
dyssynchrony in the form of broader QRS, along 
with shorter ejection and filling times, caused by 
prolonged isovolumic times. The enlargement 
Figure 2. Correlation of adiponectin with left ventricular 
mass index (LVMI) in all study patients.
Figure 4. Correlation of adiponectin with body surface 
area (BSA) in dialysis patients and controls.
Figure 5. Correlation of adiponectin with left ventricular 
mass index (LVMI) in dialysis patients and controls.
of LV volume could be interpreted on the basis 
of volume overload because of dialysis. Despite 
all these changes in LV structure and function 
adponectine did not seem to be related to any of 
them, except weakly with LVMI. Only few studies 
exist in the literature, that assessed a relationship 
between LVMI and adiponectin in dialysis patients. 
These studies include a small number of patients 
and their direct comparison with the present re-
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sults has limitations. Komaba et al. [4] included 
only diabetic patients with dialysis, and Amira et 
al. [42] found good correlation, whereas Ayerden 
Ebinç et al. [23] was the only study whose results 
were in line with ours, having found a weak cor-
relation between adiponectin and LVMI in dialysis 
patients. The strongest relationship  found herein 
was between adiponectin and BMI, which is a re-
liable measure of body fat. These results support 
the close relationship of adiponectin and its site of 
secretion, i.e. the adipose tissue, rather than with 
cardiac structure and function.   
Limitations of the study
As suggested above, the potential effect of 
volume overload during dialysis on the LV causing 
cavity enlargement, this might also have affected 
left atrial size and LV filling velocities and timing, 
hence the lack of a relationship with adiponectine. 
Right heart structure and function in this analysis 
was not included which might have shed some light 
on potential relationships, although they are also 
likely to be affected by loading conditions.
Conclusions
Although adiponectin is an established cardio-
protective marker, it does not seem to be related to 
cardiac structure and function parameters but only 
strongly to BMI suggesting an ongoing catabolic 
process associating dialysis. 
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